SEPTEMBER 10, 2025
BOARD MINUTES

GOVERNING BOARD MEETING MINUTES

Joint San Francisco Health Authority &
San Francisco Community Health Authority
Governing Board Minutes
September 10, 2025
(12:00pm to 2:00pm)

Board Attendance. In attendance were Abigail Alderson, Juthaporn Chaloeicheep, Eddie Chan, PharmD, Norlissa Cooper, PhD, MSN, MBS, RN, Steve Fugaro, MD, Roland Pickens, MHA, FACHE, Adina Safer, Daniel Tsai, Joseph Woo, MD, and Jian Zhang, DNP, MS, FNP-BC.

Absent: Johanna Liu, PharmD

Guests: Jeremy Avilla, John Puente, and James Reilly, external counsel from Epstein, Becker, and Green (EBG)

1. **Welcome.** Steven Fugaro, MD, Chair, opened the meeting. Dr. Fugaro announced that Deneen Hadley resigned from the Board. In her new position at UCLA, she was no longer eligible for the seat designated for the UCSF representative on the Board. He recognized her dedication and commitment to the plan after three years of service on the Board and as Chair of the Finance Committee. We will work with UCSF to fill the vacant seat. With Ms. Hadley's resignation, Dr. Fugaro stated the need to appoint a new Secretary/Treasurer and fill a seat on the Finance Committee. The Secretary/Treasurer also serves as the Chair of the Finance Committee. Dr. Fugaro informed the Board members to contact Yolanda R. Richardson, CEO, if they are interested. He stated this would be brought to the Board at a future meeting.

2. **Consent Calendar.** Dr. Fugaro reviewed the items on the consent calendar and informed the Board that any of the following consent items may be pulled for discussion if needed:

   a. Minutes from June 18, 2025, Board Meeting
   b. Credentialing and Recredentialing Recommendations
   c. Minutes from the Quality Improvement and Health Equity Committee meeting on May 15, 2025

   No issues were pulled from the consent calendar. Dr. Fugaro requested a motion to approve the consent calendar.

   Motion to approve the consent calendar: Roland Pickens, MHA, FACHE
   Second: Eddie Chan, PharmD
   Motion passed unanimously.

3. **Review and Approval of Year-End 2024-2025 Unaudited Financial Statements and Investment Reports.** Anne Price, Chief Finance and Strategy Officer, and Rand Takeuchi, Controller, presented the unaudited financial statements and investment income reports for the year-end 2024-2025. There were no issues or concerns raised by the Board.

   Motion to approve the year-end unaudited financial and investment reports for FY 24-25: Eddie Chan, PharmD
   Second: Jian Zhang, DNP, MS, FNP-BC

   The Board approved the motion unanimously.

4. **Review and Approval of Year-to-Date Unaudited Financial Statements and Investment Income Reports.** Ms. Price and Mr. Takeuchi reviewed the financial results and investment reports for the period ending, July 31, 2025. There were no issues or concerns raised by the Board.

   Motion to approve the year-to-date unaudited financial and investment reports: Juthaporn Chaloeicheep
   Second: Abigail Alderson

   The Board approved the motion unanimously.

5. **Review and Approval FY 2024-2025 Organizational Goals Results and Staff Bonus.** Yolanda R. Richardson, CEO, presented SFHP's results for the FY 24-25 Organizational Goals. She reported the organization achieved a score of 89% and met the financial conditions necessary for distribution of the FY 24-25 staff bonuses, with the fiscal year ending with a positive margin of $42.6 million in operations.

   Ms. Richardson requested the Board's approval for distribution of the FY 24-25 staff year-end bonus.

   Motion to approve the FY 2024-25 Organizational Goals Results and Staff Bonus: Juthaporn Chaloeicheep
   Second: Roland Pickens, MHA, FACHE

   The Board approved the motion unanimously.

6. **CEO Report.** Ms. Richardson presented highlights for the following key activities in the organization:

   a. Operational Updates
   b. State and Federal Updates
   c. D-SNP Updates

   Ms. Richardson introduced SFHP external counsel from Epstein, Becker, and Green. Jeremy Avilla, John Puente, and James Reilly provided a high-level summary of the federal policy regarding House Resolution (HR) 1 and federal payments to prohibited entities.

7. **Member Advisory Committee (MAC) Report.** Juthaporn Chaloeicheep and Abigail Alderson, the Co-Chairs of MAC, provided the MAC Committee report Abigail Alderson and Juthaporn Chaloeicheep, Co-Chairs of MAC, provided a report to the Board about the MAC meeting on September 3, 2025. There were no issues or concerns raised by the MAC that require the Board's action.

The Board Adjourned to Closed Session

8. **Review and Approval of Annual Performance Evaluation of CEO**

This item was discussed in Closed Session.

The Board resumed in Open Session

9. **Report on Closed Session Action Items.**

Dr. Fugaro reported on the action taken in Closed Session to approve the CEO's annual performance evaluation and compensation.

10. **Oral Report and Vote on Governing Board's Annual CEO Performance Evaluation and Compensation Recommendation**

Dr. Fugaro reported that the Governing Board approved the Annual Performance Evaluation of the CEO with a rating of Exemplary/Outstanding and a public announcement of the CEO's salary.

11. **Adjourned.** Dr. Fugaro adjourned the meeting.

____

Secretary/Treasurer